KYNB
KYNTRA BIO, INC.Company Information
- Company Name
- KYNTRA BIO, INC.
- CIK
- CIK0000921299
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- KYNB: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- KYNB
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-05-14
- Last sale
- 2023-09-01
- Shares purchased (TTM)
- 29,067
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 877,782
- Shares outstanding
- 4,048,000
- Ownership
- 21.68%
Earnings Market Reaction
- Filing date
- 2026-08-13
- Price on filing date
- —
- 1-month reaction
- 21.45%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 51 | 37 | 48 | 118 | 23 | 34 | 50 | 131 | 141 | 106 | 82 | 121 | ||||||
| Short Term Investments | 41 | 50 | 41 | - | - | - | 0 | 0 | 0 | 72 | 122 | 130 | ||||||
| Accounts Receivable Net Current | 0 | 5 | 0 | 0 | 0 | 0 | 0 | 29 | 6 | 37 | 5 | 32 | ||||||
| Inventory Net | 3 | 3 | 4 | 4 | 4 | 3 | 3 | 24 | 25 | 27 | 17 | 41 | ||||||
| Prepaid Expense And Other Assets Current | 2 | 6 | 6 | 11 | 2 | 3 | 32 | 61 | 37 | 36 | 40 | 40 | ||||||
| Assets Of Disposal Group Including Discontinued Operation Current | - | - | 0 | 0 | 133 | 108 | 111 | - | - | - | 66 | - | ||||||
| Assets Current | 97 | 101 | 99 | 133 | 162 | 149 | 197 | 245 | 209 | 278 | 332 | 364 | ||||||
| Restricted Cash And Cash Equivalents Noncurrent | - | - | - | - | - | - | 0 | 2 | 2 | 2 | 2 | 2 | ||||||
| Long Term Investments | 4 | 8 | 20 | 3 | - | - | 0 | - | - | - | - | - | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 3 | 3 | 3 | 3 | 4 | ||||||
| Property Plant And Equipment Net | - | - | - | - | - | - | 0 | 8 | 11 | 12 | 5 | 15 | ||||||
| Equity Method Investments | - | - | - | - | - | - | - | 6 | 7 | 6 | 5 | 5 | ||||||
| Disposal Group Including Discontinued Operation Assets Noncurrent | - | - | 0 | 0 | 15 | 16 | 17 | - | - | - | 18 | - | ||||||
| Operating Lease Right Of Use Asset | - | - | - | - | - | - | 0 | 2 | 61 | 65 | 65 | 71 | ||||||
| Assets | 101 | 110 | 120 | 137 | 178 | 165 | 215 | 264 | 293 | 366 | 424 | 460 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 8 | 5 | 4 | 5 | 10 | 7 | 5 | 9 | 10 | 4 | 16 | 19 | ||||||
| Accrued Liabilities And Other Liabilities | 23 | 17 | 20 | 26 | 36 | 35 | 62 | 151 | 114 | 164 | 133 | 171 | ||||||
| Contract With Customer Liability Current | 5 | 6 | 5 | 5 | 27 | 23 | 27 | 29 | 10 | 13 | 13 | 7 | ||||||
| Secured Debt Current | - | - | - | - | 74 | - | - | - | - | - | - | - | ||||||
| Liabilities Of Disposal Group Including Discontinued Operation Current | - | - | 0 | 0 | 8 | 8 | 39 | - | - | - | 44 | - | ||||||
| Liabilities Current | 36 | 28 | 29 | 36 | 156 | 73 | 133 | 191 | 149 | 197 | 218 | 209 | ||||||
| Operating Lease Liability Current | - | - | - | - | - | - | 0 | 1 | 16 | 15 | 13 | 12 | ||||||
| Contract With Customer Liability Noncurrent | 3 | 4 | 0 | 1 | 122 | 115 | 115 | 126 | 131 | 147 | 158 | 154 | ||||||
| Secured Long Term Debt | - | - | 0 | 0 | 0 | 73 | 73 | 73 | 72 | 72 | 72 | 72 | ||||||
| Other Liabilities Noncurrent | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 4 | 3 | 4 | ||||||
| Operating Lease Liability Noncurrent | - | - | - | - | - | - | 0 | 1 | 58 | 63 | 65 | 70 | ||||||
| Liabilities Of Disposal Group Including Discontinued Operation Noncurrent | - | - | 0 | 0 | 0 | 0 | 0 | - | - | - | 2 | - | ||||||
| Liabilities | 109 | 119 | 115 | 120 | 359 | 340 | 398 | 466 | 484 | 552 | 586 | 576 | ||||||
| Redeemable Noncontrolling Interest Equity Carrying Amount | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | ||||||
Stockholders Equity Including Portion Attributable To Noncontrolling Interest | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Additional Paid In Capital | 1,680 | 1,679 | 1,677 | 1,676 | 1,673 | 1,671 | 1,669 | 1,668 | 1,661 | 1,652 | 1,644 | 1,634 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -1 | -2 | -2 | -2 | -5 | -4 | -6 | -6 | -4 | -7 | -7 | -7 | ||||||
| Retained Earnings Accumulated Deficit | -1,709 | -1,721 | -1,706 | -1,692 | -1,892 | -1,885 | -1,889 | -1,907 | -1,890 | -1,875 | -1,842 | -1,786 | ||||||
| Stockholders Equity | -30 | -44 | -17 | -17 | -223 | -196 | -205 | -223 | -212 | -208 | -184 | -157 | ||||||
| Nonredeemable Noncontrolling Interest | 1 | 13 | 13 | 13 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | ||||||
| Liabilities And Stockholders Equity | 101 | 110 | 120 | 137 | 178 | 165 | 215 | 264 | 293 | 366 | 424 | 460 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Preferred Stock Shares Authorized | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Common Stock Shares Authorized | 225 | 225 | 225 | 225 | 225 | 225 | 225 | 225 | 225 | 225 | 225 | 225 | ||||||
| Common Stock Shares Issued | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | ||||||
| Shares Outstanding | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialKYNTRA BIO, INC. (KYNB) — SEC Financial Statements & Analysis
KYNTRA BIO, INC. (KYNB) is a pharmaceutical preparations company. KYNTRA BIO, INC. trades on Nasdaq as: KYNB. KYNTRA BIO, INC. (KYNB)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, KYNTRA BIO, INC. carries a market cap of $30.56M, a P/E ratio of 0.17x, a P/B ratio of -1.03x, a P/S ratio of 6.62x, an enterprise value of $-20.08M, and an EV/EBITDA multiple of 0.40x. On profitability, it posts a gross margin of 6.28%, an operating margin of -1089.78%, a net margin of 3967.77%, a Return on Equity (ROE) of -145.03%, and a Return on Assets (ROA) of 131.26%. Per share, it reports EPS of $45.25, diluted EPS of $45.25, free cash flow per share of $-9.40, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -37.15% year-over-year, net income growth of -8966.99% year-over-year, and EPS growth of -8953.85% year-over-year. On the balance sheet, it maintains a current ratio of 2.69x, a quick ratio of 2.54x, working capital of $60.78M, a debt-to-equity ratio of -3.69x, a debt ratio of 1.08, an interest coverage ratio of -5.42x, free cash flow of $-38.06M (TTM), and net debt of $-50.64M. Figures sourced from SEC EDGAR.
- Market Cap
- $30.56M
- P/E TTM
- 0.17x
- EPS TTM
- $45.25
- P/B TTM
- -1.03x
- ROE TTM
- -145.03%
- ROA TTM
- 131.26%
- Debt To Equity
- -3.69x
- Free Cash Flow TTM
- $-38.06M
- Net Revenue TTM Growth 1Y
- -37.15%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is KYNTRA BIO, INC. in?
KYNTRA BIO, INC. (KYNB) operates in the Pharmaceutical Preparations industry.
What exchange does KYNB trade on?
KYNTRA BIO, INC. (KYNB) trades on the Nasdaq.
When was KYNTRA BIO, INC. (KYNB)'s most recent SEC filing?
KYNTRA BIO, INC. (KYNB)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13.
What is KYNB's market cap?
KYNTRA BIO, INC. (KYNB) has a market capitalization of $30.56M as of 2026-06-30.
What is KYNB's P/E ratio?
KYNTRA BIO, INC. (KYNB)'s trailing twelve month P/E ratio is 0.17x as of 2026-06-30.
What is KYNB's EPS (earnings per share)?
KYNTRA BIO, INC. (KYNB)'s trailing twelve month EPS is $45.25 as of 2026-06-30.
What is KYNB's ROE (return on equity)?
KYNTRA BIO, INC. (KYNB)'s trailing twelve month Return on Equity (ROE) is -145.03% as of 2026-06-30.
What is KYNB's ROA (return on assets)?
KYNTRA BIO, INC. (KYNB)'s trailing twelve month Return on Assets (ROA) is 131.26% as of 2026-06-30.
What is KYNB's EV/EBITDA?
KYNTRA BIO, INC. (KYNB)'s trailing twelve month EV/EBITDA is 0.40x as of 2026-06-30.